Argenx Tumbles 2.23% on $320M Volume Ranking 379th as Analysts Clash Over BuyHold Stances

On August 5, 2025, Argenx (ARGX) closed down 2.23% with a trading volume of $0.32 billion, ranking 379th in market activity. The stock’s performance coincided with mixed analyst coverage as major institutions updated their stance on the biopharmaceutical company.

J.P. Morgan analyst James Gordon reiterated a "Buy" rating for Argenx, maintaining a $830.00 price target. Gordon, a 3-star analyst with a 55.16% success rate, highlighted the firm’s recent financial results, including a $738.41 million quarterly revenue and $835.54 million net profit, contrasting sharply with last year’s GAAP net loss of $155.63 million. Citigroup’s Samantha Semenkow also issued a "Buy" recommendation earlier in August, though UBS opted to maintain a "Hold" rating on the same day, reflecting divergent views on the stock’s short-term trajectory.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets. The returns generated from this strategy far exceed the performance of a buy-and-hold approach, indicating that liquidity-driven strategies can be potent in capturing short-term market movements.